title: Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
abstract: Monoclonal antibody 791T/36, recognizing a Mr 72,000 antigen on the surface of colon carcinoma cells, has been used to construct an immunotoxin by conjugating to it the ribosomal inhibitor protein, ricin toxin A chain. The antibody 791T/36 has been shown to bind to membranes of freshly disaggregated tumor cells from human colon tumors, and to localize in tumors in vivo. Subacute toxicology testing in rats receiving immunotoxin i.v. showed, at highest doses, weight loss, decreased serum albumin, and hepatocyte vacuolization without elevation in liver function tests. A Phase I dose escalation study was carried out in which 17 patients with metastatic colorectal cancer were treated with doses of immunotoxin ranging from 0.02 to 0.2 mg/kg/day in 1-h i.v. infusions for a 5-day course. Side-effects included a composite of signs and symptoms thought to be generic to ricin A chain immunotoxins, including decreased serum albumin, mild fever, and flu-like symptoms, all being reversible. Two additional findings, reversible proteinuria and mental status changes, were also noted which may be characteristic of this immunotoxin. By 10-20 days after therapy, most patients developed IgM and IgG antibodies against both the ricin toxin A chain and the immunoglobulin portion of the immunotoxin, which were asymptomatic. A strong anticombining site antibody response was seen. Biological activity manifest as mixed tumor regression was seen in five patients.
authors: XOMA Corporation, Berkeley, California.
authors: V S
authors: VS
authors: Byers
authors: R
authors: R
authors: Rodvien
authors: K
authors: K
authors: Grant
authors: L G
authors: LG
authors: Durrant
authors: K H
authors: KH
authors: Hudson
authors: R W
authors: RW
authors: Baldwin
authors: P J
authors: PJ
authors: Scannon
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use / Q000633:toxicity; D000917:Antibody Formation; D002272:Carcinoembryonic Antigen / Q000032:analysis; D003110:Colonic Neoplasms / Q000276:immunology / Q000628:therapy*; D004341:Drug Evaluation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D000922:Immunotoxins / Q000009:adverse effects* / Q000627:therapeutic use / Q000633:toxicity; D007928:Lethal Dose 50; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000276:immunology / Q000556:secondary* / Q000628:therapy; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary* / Q000628:therapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D009362:Neoplasm Metastasis; D051381:Rats; D011919:Rats, Inbred Strains; D012276:Ricin / Q000009:adverse effects* / Q000627:therapeutic use / Q000633:toxicity; D012709:Serum Albumin / Q000032:analysis
chemical_list: D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D000922:Immunotoxins; D012709:Serum Albumin; C059257:XomaZyme; D012276:Ricin